274 related articles for article (PubMed ID: 29270008)
1. Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.
Omote N; Hashimoto N; Morise M; Sakamoto K; Miyazaki S; Ando A; Nakahara Y; Hasegawa Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3541-3547. PubMed ID: 29270008
[TBL] [Abstract][Full Text] [Related]
2. Impact of chemotherapy in the prognosis of non-small-cell lung cancer patients with severe to very severe COPD.
Dong W; Du Y; Ma S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3805-3812. PubMed ID: 30538442
[TBL] [Abstract][Full Text] [Related]
3. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy.
Dong W; Zhu Y; Du Y; Wang L; Feng X; Ma S
Clin Respir J; 2020 Apr; 14(4):345-352. PubMed ID: 31876095
[TBL] [Abstract][Full Text] [Related]
4. Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors.
Izquierdo JL; Resano P; El Hachem A; Graziani D; Almonacid C; Sánchez IM
Int J Chron Obstruct Pulmon Dis; 2014; 9():1053-8. PubMed ID: 25336937
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2019; 14():929-938. PubMed ID: 31118602
[No Abstract] [Full Text] [Related]
6. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.
Volpino P; Cangemi R; Fiori E; Cangemi B; De Cesare A; Corsi N; Di Cello T; Cangemi V
J Cardiovasc Surg (Torino); 2007 Jun; 48(3):375-83. PubMed ID: 17505444
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of and risk factors for postoperative pulmonary complications after lung cancer surgery in patients with early-stage COPD.
Kim ES; Kim YT; Kang CH; Park IK; Bae W; Choi SM; Lee J; Park YS; Lee CH; Lee SM; Yim JJ; Kim YW; Han SK; Yoo CG
Int J Chron Obstruct Pulmon Dis; 2016; 11():1317-26. PubMed ID: 27366059
[TBL] [Abstract][Full Text] [Related]
8. [Impact of Chronic Obstructive Pulmonary Disease on Risk of Recurrence in Patients with Resected Non-small Cell Lung Cancer].
Qiang G; Yu Q; Liang C; Song Z; Shi B; Guo Y; Liu D
Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):215-220. PubMed ID: 29587946
[TBL] [Abstract][Full Text] [Related]
9. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.
Shin SH; Park HY; Im Y; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee HY; Lee SH
Int J Cancer; 2019 Nov; 145(9):2433-2439. PubMed ID: 30807641
[TBL] [Abstract][Full Text] [Related]
10. Impact of chronic obstructive pulmonary disease on postoperative recurrence in patients with resected non-small-cell lung cancer.
Qiang G; Liang C; Xiao F; Yu Q; Wen H; Song Z; Tian Y; Shi B; Guo Y; Liu D
Int J Chron Obstruct Pulmon Dis; 2016; 11():43-9. PubMed ID: 26766906
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
Sawa K; Koh Y; Kawaguchi T; Kambayashi S; Asai K; Mitsuoka S; Kimura T; Yoshimura N; Yoshimoto N; Kubo A; Saka H; Matsumura A; Wanibuchi H; Yamamoto N; Nishiyama N; Hirata K
Lung Cancer; 2017 Oct; 112():96-101. PubMed ID: 29191607
[TBL] [Abstract][Full Text] [Related]
12. Comorbid pulmonary disease and risk of community-acquired pneumonia in COPD patients.
Lin SH; Ji BC; Shih YM; Chen CH; Chan PC; Chang YJ; Lin YC; Lin CH
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1638-44. PubMed ID: 24200282
[TBL] [Abstract][Full Text] [Related]
13. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
Yi YS; Ban WH; Sohng KY
BMC Cancer; 2018 Oct; 18(1):1053. PubMed ID: 30373585
[TBL] [Abstract][Full Text] [Related]
14. Personalized pulmonary rehabilitation and occupational therapy based on cardiopulmonary exercise testing for patients with advanced chronic obstructive pulmonary disease.
Maekura R; Hiraga T; Miki K; Kitada S; Miki M; Yoshimura K; Yamamoto H; Kawabe T; Mori M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1787-800. PubMed ID: 26366071
[TBL] [Abstract][Full Text] [Related]
15. Preoperative spirometry results as a determinant for long-term mortality after EVAR for AAA.
Ohrlander T; Dencker M; Acosta S
Eur J Vasc Endovasc Surg; 2012 Jan; 43(1):43-7. PubMed ID: 22051733
[TBL] [Abstract][Full Text] [Related]
16. Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
Jeppesen SS; Hansen NG; Schytte T; Nielsen M; Hansen O
Lung Cancer; 2016 Oct; 100():90-95. PubMed ID: 27597286
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2018; 13():2139-2146. PubMed ID: 30034229
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
Ajimizu H; Ozasa H; Sato S; Funazo T; Sakamori Y; Nomizo T; Kuninaga K; Ogimoto T; Hosoya K; Yamazoe M; Tsuji T; Yoshida H; Itotani R; Ueno K; Kim YH; Muro S; Hirai T
Sci Rep; 2021 Dec; 11(1):23677. PubMed ID: 34880386
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
